Cipla’s US recovery, biosimilar pipeline key to future growth prospects

Cipla's US business has started to recover, helping to offset the impact of a high base in its previous performance. This recovery, combined with the company's growing biosimilar pipeline, is key to its future growth prospects. The growth in its India business and branded prescription therapies also contributed to its sequential growth in the September quarter. As Cipla anticipates improvements in operating margins with new product launches, investors will be watching closely to see if these plans come to fruition.

Why it matters

Cipla's US recovery and biosimilar pipeline are key to its future growth prospects. The company reported sequential growth driven by its strong India business.

Market impact

Markets & countries in focus

Transmission channels

Likely winners & losers

Explore the intelligence

MeridStreet does not reproduce source articles. The summary and analysis above are generated by MeridStreet from public headlines and its own market model; the original reporting belongs to Economic Times. For information only — not financial advice.